FAQ| NEWLY DIAGNOSED | SYMPTOMS | CHAT ROOM & message BOARDS| in memory of Janis

JANIS AND FRIENDS HEPATITIS C WEB SITE

latest news

HOME

HCV NEWS

INTERNET CONFERENCES

HCV TRIALS

WHATS NEW AT J&F

HCV ARCHIVES

page updates

VX950-TELAPREVIR

other HCV Information

HISTORY OF HCV

GLOSSARY/ABBREVIATIONS

LIVER FUNCTIONS

QUESTIONS ABOUT HCV

EXTRAHEPATIC CONDITIONS

SYMPTOMS

TRANSMISSION

SEXUAL TRANSMISSION

HCV BLOOD TESTS/LABS

LABS ON TREATMENT

BIOPSY RESULTS

ALTERNATIVE TO BIOPSY

STILL NEED A BIOPSY ?

ON BIOPSY WHAT DOES THE STAGE MEAN AND WHAT DOES THE GRADE ME ?

STAGES/LIVER DISEASE

FIBROSIS

CIRRHOSIS

TRANSPLANTS

LIVER CANCER

GENOTYPES

VIRAL LOAD

PEGASYS/ PEGINTRON

INFERGEN

HELP/SIDE EFFECTS

DRUG INTERACTIONS

NUTRITION & HCV

TREATMENT STORIES

FIRST SHOT

INTERVIEWS

FIND A DOCTOR

FINANCIAL AID/MED ETC

SUPPORT GROUPS/TRANSPLANTS

HCV SUPPORT GROUPS

PICTURES Of OUR FRIENDS

INFORMATIONAL LINKS

This Web Site is committed to the memory of Janis Morrow.

Human liver

Articles on all genotypes & Latest Treatments

2006 Index

Back to 2005 Research

Page One Page Three Page Four

2003 Articles 2002-2001 Articles

Back to Main Genotype Page

2006 Index

Nov

Coverage of 57th Annual Meeting of the American Association for the Study of Liver Disease

Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with

Genotype 1 11/03/06

Risk Factors for Relapse in Patients with High Viral Load and Genotype 3 Hepatitis C in the WIN-R Trial 11/03/06

Pegasys plus Ribavirin for 16 versus 24 Weeks in Patients with HCV

Genotype 2 11/03/06

Risk Factors for Relapse in Patients with High Viral Load and

Genotype 3 Hepatitis C in the WIN-R Trial 11/03/06

Treatment Extension to 72 Weeks of PegIntron plus Weight-based Ribavirin Improves SVR Rates in Difficult-to-Treat Slow Responders with

Genotype 1 11/03/06

AUG

Distribution of Hepatitis C Virus Genotypes and Viral Load Levels in the U.S.

24-Week vs 48-Week Treatment with Pegasys Plus Ribavirin in HCV Genotype 1 Patient

JULY

Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients -

JUNE

Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment For Patients

Differences in Outcomes of Treatment with PegIntron Plus Fixed-dose or Weight-based Ribavirin Based on Genotype and Viral Load in HCV Genotypes 2 and 3 in The WIN-R Trial -

3 New Combination Therapies

New Phase 2 Studies of HCV Protease Inhibitor VX-950 Will Evaluate SVR Rates in Patients with HCV Genotype 1

Abstract T1814 – A randomized trial comparing Short Course versus Standard Treatment with non-pegylated interferon α and ribavirin in patients with Chronic Hepatitis C Genotype 3 Virus Infection.

Hepatic Iron, Liver Steatosis and HCV Genotypes in Patients with Chronic Hepatitis C -

Hispanic Patients with Genotype 2 or 3 Chronic Hepatitis C have Lower Rates of Sustained Virologic Response to Treatment with Pegylated Interferon and Ribavirin.

5/23/06

Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin in the Retreatment of Interferon/Ribavirin Nonresponders

Comparison of 48 vs 72 Weeks of Treatment with Peginterferon Alfa-2a plus Ribavirin in Patients with HCV Genotype 1

Factors That Predict a Rapid Virological Response at Week 4 and a Sustained Virological Response at Week 24

Blacks with HCV Genotype 1 (but Not Genotypes 2 or 3) Have a Lower SVR Rate Than Non-Blacks That Is Not Related to Dose Reductions of Interferon and Ribavirin

24 Weeks Treatment with Peginterferon Alfa-2b (PegIntron) plus Ribavirin Is Efficacious in Patients with Chronic HCV Genotype 1 and Low Pretreatment HCV RNA Levels

Interim Results of Studies of Albuferon plus Ribavirin in Nonresponders and in Treatment-naïve Patients with HCV Genotype 1 - 3/17/06

Pilot Study of Interferon-alfa+Ribavirin+Interleukin-2 for Treatment of Hepatitis C Virus Genotype 1 Patients with Severe Liver Disease Hepatitis -

Treatment of Genotype 1 Chronic Hepatitis C: Increased Sustained Virological Response with High-dose RBV and Epoetin

Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study

Short-term Treatment Duration for HCV Genotypes 2 and 3 Patients

Small Study Shows HCV RNA Levels Undetectable in 12 of 12 HCV Genotype 1 Patients after 4 Weeks of Treatment with Experimental HCV Drug VX 950 Plus Pegasys and Ribavirin - 2/10/06

Valopicitabine Dosed in Combination with Pegylated Interferon Alfa-2a (Pegasys) Leads to Rapid Virologic Response in 93 percent of Genotype 1 Hepatitis C Patients - 1/10/06

For more information visit HIV&Hepatitis Site

http://www.hivandhepatitis.com/hep_c/hepc_news_genotype.html#five